Search

Your search keyword '"Voskuyl, Alexandre"' showing total 874 results

Search Constraints

Start Over You searched for: Author "Voskuyl, Alexandre" Remove constraint Author: "Voskuyl, Alexandre"
874 results on '"Voskuyl, Alexandre"'

Search Results

1. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy

2. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

3. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

4. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses

5. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies

6. [18F]Fluoride PET provides distinct information on disease activity in ankylosing spondylitis as compared to MRI and conventional radiography

8. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands

10. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

13. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

14. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

15. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study

16. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

18. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

19. Does Adding Single‐Nucleotide Polymorphisms to Risk Algorithms Improve Cardiovascular Disease Risk Prediction in Rheumatoid Arthritis? An Internal and External Validation of a Clinical Risk Score.

23. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

29. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy.

31. Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations

32. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases:long-term humoral immune responses and effects on disease activity

33. Identification of new risk loci and pathways involved in GCA pathogenesis by a genome-wide.

34. Sensing of latent EBV infection through exosomal transfer of 5′pppRNA

35. Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

36. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

37. Longitudinal Dynamics of the SARS-CoV-2 Antibody Repertoire after SARS-CoV-2 Delta and Omicron Breakthrough Infections in Patients with Immune-Mediated Inflammatory Diseases

38. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

39. [18F]Fluoride PET provides distinct information on disease activity in ankylosing spondylitis as compared to MRI and conventional radiography

41. Recurrence risk of venous thromboembolism associated with systemic lupus erythematosus: A retrospective cohort study

42. SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period

43. Additional file 1 of Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

44. Favourable effect of a ‘second hit’ after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial

45. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

47. Favourable effect of a 'second hit' after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial.

48. Positron Emission Tomography to Improve Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation

49. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study

50. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

Catalog

Books, media, physical & digital resources